Urine Toxicology Testing in Chronic Pain Management

References

• . American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2004;100(6):1573–1581
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Cancer Pain Relief. 2nd ed. Geneva, Switzerland: WHO Office of Publication; 1996
   Google Scholar
• . American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, IL: American Pain Society; 2003
   Google Scholar
• . Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology. 1996;84(5):1243–1257
   PubMedGoogle Scholar
• . AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50( 6 suppl):S205–S224
   PubMed Web of Science ®Google Scholar
• . Chou R, Qaseem A, Snow V, ; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478–491
   PubMed Web of Science ®Google Scholar
• . American Pain Society. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. Chicago, IL: American Pain Society; 2002
   Google Scholar
• . Bhamb B, Brown D, Hariharan J, Anderson J, Balousek S, Fleming MF. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22(9):1859–1865
   PubMed Web of Science ®Google Scholar
• . Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652–655
   PubMed Web of Science ®Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, ; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15(3):184–191
   PubMed Web of Science ®Google Scholar
• . Preston KL, Silverman K, Schuster CR, Cone EJ. Comparison of self-reported drug use with quantitative and qualitative urinalysis for assessment of drug use in treatment studies. NIDA Res Monogr. 1997;167:130–145
   PubMedGoogle Scholar
• . Katz NP, Sherburne S, Beach M, . Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097–1102
   PubMed Web of Science ®Google Scholar
• . Yang JM. Toxicology and drugs of abuse testing at the point of care. Clin Lab Med. 2001;21(2):363–374
   PubMedGoogle Scholar
• . Reisfield GM, Bertholf R, Barkin RL, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007;3(2):80–86
   PubMedGoogle Scholar
• . Reisfield GM, Webb FJ, Bertholf RL, Sloan PA, Wilson GR. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag. 2007;3(6):333–337
   PubMedGoogle Scholar
• . Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D. Prevalence of chronic pain in a representative sample in the United States. Pain Med. 2008;9(7):803–812
   PubMed Web of Science ®Google Scholar
• . 1999 National Pain Survey: Executive Summary. Ortho-McNeil Pharmaceutical. http://www.chiro.org/LINKS/FULL/1999_National_Pain_Survey.html. Accessed June 2, 2009
   Google Scholar
• . SAMHSA. Results from the 2002 National Survey on Drug Use and Health: National Findings, DHHS Publication No. SMA 03-3836. Rockville, MD: Department of Health and Human Services; 2003
   Google Scholar
• . Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444–459
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Manchukonda R, Pampati V, . Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123–129
   PubMedGoogle Scholar
• . Manchikanti L, Fellows B, Damron KS, Pampati V, McManus CD. Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: an evaluation of patterns and trends. J Ky Med Assoc. 2005;103(2):55–62
   PubMedGoogle Scholar
• . Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9(1):57–60
   PubMedGoogle Scholar
• . Manchikanti L, Pampati V, Damron KS, Fellows B, Barnhill RC, Beyer CD. Prevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluation. Pain Physician. 2001;4(4):358–365
   PubMedGoogle Scholar
• . Manchikanti L, Pampati V, Damron KS, Beyer CD, Barnhill RC, Fellows B. Prevalence of prescription drug abuse and dependency in patients with chronic pain in western Kentucky. J Ky Med Assoc. 2003;101(11):511–517
   PubMedGoogle Scholar
• . Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain. 2008;24(6):497–508
   PubMed Web of Science ®Google Scholar
• . Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta. 2002;315(1-2):125–135
   PubMed Web of Science ®Google Scholar
• . Bush DM. The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations. Forensic Sci Int. 2008;174(2-3):111–119
   PubMed Web of Science ®Google Scholar
• . Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg. 2000;55(6):323–333
   PubMed Web of Science ®Google Scholar
• . Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37(4):301–314
   PubMed Web of Science ®Google Scholar
• . Crouch DJ, Hersch RK, Cook RF, Frank JF, Walsh JM. A field evaluation of five on-site drug-testing devices. J Anal Toxicol. 2002;26(7):493–449
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Dickerson S, Paul BD, Mitchell JM. Forensic drug testing for opiates. IV. Analytical sensitivity, specificity, and accuracy of commercial urine opiate immunoassays. J Anal Toxicol. 1992;16(2):72–78
   PubMedGoogle Scholar
• . Smith ML, Hughes RO, Levine B, Dickerson S, Darwin WD, Cone EJ. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol. 1995;19(1):18–26
   PubMedGoogle Scholar
• . Caplan YH. Specimen validity testing. In: Karch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press; 2007:842–856
   Google Scholar
• . Cook JD, Caplan YH, LoDico CP, Bush DM. The characterization of human urine for specimen validity determination in workplace drug testing: a review. J Anal Toxicol. 2000;24(7):579–588
   PubMed Web of Science ®Google Scholar
• . Cody JT, Valtier S, Kuhlman J. Analysis of morphine and codeine in samples adulterated with Stealth. J Anal Toxicol. 2001;25(7):572–575
   PubMed Web of Science ®Google Scholar
• . Wu AH, Bristol B, Sexton K, Cassella-McLane G, Holtman V, Hill DW. Adulteration of urine by “Urine Luck.” Clin Chem. 1999;45(7): 1051–1057
   PubMed Web of Science ®Google Scholar
• . US Department of Transportation. Urine Specimen Collection Guidelines. US Department of Transportation; 2008
   Google Scholar
• . US Nuclear Regulatory Commission. Checking the acceptability of the urine specimen. US Nuclear Regulatory Commission; 2008
   Google Scholar
• . Cook JD, Strauss KA, Caplan YH, Lodico CP, Bush DM. Urine pH: the effects of time and temperature after collection. J Anal Toxicol. 2007;31(8):486–496
   PubMed Web of Science ®Google Scholar
• . Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit. 2003;25(6):723–727
   PubMedGoogle Scholar
• . Department of Health and Human Services. Mandatory guidelines for federal workplace drug testing programs; notice. Federal Registry. 2008;73:71858–71907
   Google Scholar
• . Luzzi VI, Saunders AN, Koenig JW, . Analytic performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem. 2004;50(4):717–722
   PubMedGoogle Scholar
• . Smith ML, Shimomura ET, Summers J, . Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration. J Anal Toxicol. 2000;24(7):522–529
   PubMedGoogle Scholar
• . McDonough PC, Levine B, Vorce S, Jufer RA, Fowler D. The detection of hydromorphone in urine specimens with high morphine concentrations. J Forensic Sci. 2008;53(3):752–754
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Caplan YH, Moser F, Robert T, Black D. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32(4):319–323
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006;30(1):1–5
   PubMed Web of Science ®Google Scholar
• . Kirchheiner J, Schmidt H, Tzvetkov M. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257–265
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Jufer R, Darwin WD, Needleman SB. Forensic drug testing for opiates. VII. Urinary excretion profile of intranasal (snorted) heroin. J Anal Toxicol. 1996;20(6):379–392
   PubMedGoogle Scholar
• . Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med. 1984;310(19):1213–1217
   PubMed Web of Science ®Google Scholar
• . OxyContin⊙ [package insert]. Stamford, CT: Purdue Pharma LP; 2007
   Google Scholar
• . Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag. 2008;4(3):131–144
   PubMedGoogle Scholar
• . Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician. 2007;10(3):399–424
   PubMedGoogle Scholar
• . Hydrocodone [package insert]. Corona, CA: Watson Laboratories; 2004
   Google Scholar
• . Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24(7):530–535
   PubMed Web of Science ®Google Scholar
• . Yue QY, Alm C, Svensson JO, Saäe J. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit. 1997;19(5):539–542
   PubMedGoogle Scholar
• . Hamid R, Deren S, Beardsley M, Tortu S. Agreement between urinalysis and self-reported drug use. Subst Use Misuse. 1999;34(11):1585–1592
   PubMed Web of Science ®Google Scholar
• . Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18( 4 suppl):S76–S82
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Fant RV, Rohay JM, . Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol. 2004;28(7):616–624
   PubMedGoogle Scholar
• . Cone EJ, Fant RV, Rohay JM, . Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27(2):57–67
   PubMed Web of Science ®Google Scholar
• . Denton JS, Donoghue ER, McReynolds J, Kalelkar MB. An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J Forensic Sci. 2008;53(2):452–454
   PubMedGoogle Scholar
• . Hull MJ, Juhascik M, Mazur F, Flomenbaum MA, Behonick GS. Fatalities associated with fentanyl and co-administered cocaine or opiates. J Forensic Sci. 2007;52(6):1383–1388
   PubMed Web of Science ®Google Scholar
• . Shields LB, Hunsaker Iii JC, Corey TS, Ward MK, Stewart D. Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007;52(6):1389–1395
   PubMed Web of Science ®Google Scholar
• . Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM. Methadone-related deaths in Palm Beach County. J Forensic Sci. 2004;49(2):375–378
   PubMedGoogle Scholar
• . Manchikanti L, Damron KS, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study. Pain Physician. 2004;7(4):431–I37
   PubMedGoogle Scholar
• . Parsons HA, Delgado-Guay MO, El Osta B, . Alcoholism screening in patients with advanced cancer: impact on symptom burden and opioid use. J Palliat Med. 2008;11(7):964–968
   PubMed Web of Science ®Google Scholar
• . Kadian⊙ [package insert]. Piscataway, NJ: Alpharma, 2007
   Google Scholar
• . OPANA ER⊙ [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2008
   Google Scholar
• . Duragesic⊙ [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2008
   Google Scholar
• . Dilaudid-HP⊙ [package insert]. Chicago, IL: Abbott Laboratories; 2008
   Google Scholar
• . DeRienz RT, Holler JM, Manos ME, Jemionek J, Past MR. Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine. J Anal Toxicol. 2008;32(6):433–437
   PubMedGoogle Scholar
• . Elian AA. ELISA detection of clonazepam and 7-aminoclonazepam in whole blood and urine. Forensic Sci Int. 2003;134(1):54–56
   PubMedGoogle Scholar
• . Joseph R, Dickerson S, Willis R, Frankenfield D, Cone EJ, Smith DR. Interference by nonsteroidal anti-inflammatory drugs in EMIT and TDx assays for drugs of abuse. J Anal Toxicol. 1995;19(1):13–17
   PubMedGoogle Scholar
• . Stout PR, Klette KL, Horn CK. Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci. 2004;49(1):160–164
   PubMedGoogle Scholar
• . Roberge RJ, Luellen JR, Reed S. False-positive amphetamine screen following a trazodone overdose. J Toxicol Clin Toxicol. 2001;39(2):181–182
   PubMed Web of Science ®Google Scholar
• . Maurer HH, Kraemer T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch Toxicol. 1992;66(9):675–678
   PubMedGoogle Scholar
• . Weintraub D, Linder MW. Amphetamine positive toxicology screen secondary to bupropion. Depress Anxiety. 2000;12(1):53–54
   PubMed Web of Science ®Google Scholar
• . Nagai T, Matsushima K, Nagai T, . Interpretation and enantiomer analysis of methamphetamine abusers' urine and illegally brewed methamphetamine crystals. J Anal Toxicol. 2000;24(2):140–145
   PubMedGoogle Scholar
• . Al-Dirbashi O, Wada M, Kuroda N, Inuduka S, Nakashima K. Enantiomer-specific high-performance liquid chromatography with fluorescence detection of methamphetamines in abusers' hair and urine. Biomed Chromatogr. 1999;13(8):543–547
   PubMedGoogle Scholar
• . Cone EJ, Johnson RE, Darwin WD, . Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol. 1987;11(3):89–96
   PubMed Web of Science ®Google Scholar
• . Niedbala S, Kardos K, Salamone S, Fritch D, Bronsqeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol. 2004;28(7):546–552
   PubMed Web of Science ®Google Scholar
• . SUSTIVA⊙ [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2002
   Google Scholar
• . PROTONIX⊙ [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008
   Google Scholar
• . Fortner N, Fogerson R, Lindman D, Iversen T, Armbruster D. Marijuana-positive urine test results from consumption of hemp seeds in food products. J Anal Toxicol. 1997;21(6):476–481
   PubMedGoogle Scholar
• . Struempler RE, Nelson G, Urry FM. A positive cannabinoids workplace drug test following the ingestion of commercially available hemp seed oil. J Anal Toxicol. 1997;21(4):283–285
   PubMedGoogle Scholar
• . Bosy TZ, Cole KA. Consumption and quantitation of delta9-tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol. 2000;24(7):562–566
   PubMed Web of Science ®Google Scholar
• . Gustafson RA, Levine B, Stout PR, . Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem. 2003;49(7):1114–1124
   PubMedGoogle Scholar
• . Bergström J, Helander A, Jones AW. Ethyl glucuronide concentrations in two successive urinary voids from drinking drivers: relationship to creatinine content and blood and urine ethanol concentrations. Forensic Sci Int. 2003;133(1–2):86–94
   PubMedGoogle Scholar
• . Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use. Addiction. 2003;98( suppl 2):51–61
   PubMed Web of Science ®Google Scholar
• . Beck O, Stephanson N, Böttcher M, Dahmen N, Fehr C, Helander A. Biomarkers to disclose recent intake of alcohol: potential of 5-hydroxytryptophol glucuronide testing using new direct UPLC-tandem MS and ELISA methods. Alcohol Alcohol. 2007;42(4):321–325
   PubMed Web of Science ®Google Scholar
• . Böttcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol. 2008;43(1):46–48
   PubMed Web of Science ®Google Scholar
• . U.S. Department of Health and Human Services, Center for Substance Abuse Treatment. The Role of Biomarkers in the Treatment of Alcohol Use Disorders; 2006
   Google Scholar
• . Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone—metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50(6): 551–559
   PubMed Web of Science ®Google Scholar
• . The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6–8
   PubMed Web of Science ®Google Scholar
• . Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22(4):485–490
   PubMed Web of Science ®Google Scholar
• . Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129(3):355–362
   PubMed Web of Science ®Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131–146
   PubMed Web of Science ®Google Scholar
• . Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307–315
   PubMed Web of Science ®Google Scholar
• . Webster LR, Webster RM. Predicting aberrant behaviors in opioid treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–142
   PubMed Web of Science ®Google Scholar
• . Butler SF, Budman SH, Fernandez KC, . Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144–156
   PubMed Web of Science ®Google Scholar
• . Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372
   PubMed Web of Science ®Google Scholar
• . Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107–112
   PubMed Web of Science ®Google Scholar
• . Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70–83
   PubMed Web of Science ®Google Scholar
• . American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions Related to the Use of Opioids for the Treatment of Pain. A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Glenview, IL: 2001
   Google Scholar
• . Weaver MF, Jarvis MA, Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med. 1999;159(9):913–924
   PubMed Web of Science ®Google Scholar
• . Prater CD, Miller KE, Zylstra RG. Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician. 1999;60(4): 1175–1183
   PubMed Web of Science ®Google Scholar
• . Polcin DL. Rethinking confrontation in alcohol and drug treatment: consideration of the clinical context. Subst Use Misuse. 2003;38(2): 165–184
   PubMed Web of Science ®Google Scholar
• . Heit HA. The truth about pain management: the difference between a pain patient and an addicted patient. Eur J Pain. 2001;5( suppl A):27–29
   PubMedGoogle Scholar
• . Weaver M, Schnoll S. Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain. 2002;18( 4 suppl):S61–S69
   PubMed Web of Science ®Google Scholar
• . The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6–8
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624
   PubMed Web of Science ®Google Scholar